FemTech’s Data Problem: Why the Future of Healthcare Requires Rethinking How We Measure Women’s Health
After a discussion with Roswitha Verwer and Dr. Muskaan Bhan, Dr. Peter M. Kovacs examines the hidden data bias in healthcare and explains why FemTech innovation, continuous biomarker tracking, and inclusive medical data are essential for the future of women’s health and AI-driven medicine.
Execution Under Pressure: What Building a FemTech Company Reveals About Leadership, Capital, and Discipline
Dr. Peter M. Kovacs, in conversation with Roswitha Verwer and Károly Szántó, explores why execution discipline, governance, and aligned capital determine whether early-stage healthcare startups accelerate or stall in regulated industries like biotech, medtech, and femtech.
The Co-Investor Question: Why Capital Alone Does Not Build Biotech Winners
In biotech, the right co-investor determines success.
Peter M. Kovacs explains why alignment, execution discipline, and operational de-risking matter more than capital alone in building resilient, high-performing biotech and MedTech companies.
Europe’s Deep Tech Paradox: World-Class Science, Invisible Companies
In this article, Dr. Peter M. Kovacs draws on his discussion with Thijmen Meijer and Károly Szántó to explain why Europe’s startup gap is not a capital shortage but a translation failure, and sets out what must change to convert scientific excellence into globally competitive deep-tech companies.